Literature DB >> 24560439

[Gastroenteropancreatic neuroendocrine tumors: clinical characteristics, diagnosis and prognosis at Hospital Universitario Clínico San Carlos (Madrid)].

María Paz de Miguel Novoa1, Francisco Fernández Capel2, Jesús Vicente Redondo Sedano2, Margarita Sellers Carrera2, Verónica Aranda Jiménez2, Paloma Ortiz Pereira2, Javier Sastre Valera2, Luis Ortega Medina2, José Ángel Díaz Pérez2.   

Abstract

INTRODUCTION: Neuroendocrine tumors are a group of neoplasms arising from the neural crest and endoderm and very heterogeneous as regards localization, clinical behavior, aggressiveness, and prognosis. Pancreas and gastrointestinal tract are the most common sites where neuroendocrine tumors can be found.
MATERIAL AND METHODS: A review was made of all cases of neuroendocrine tumors diagnosed at Hospital Universitario Clínico San Carlos (HUCSC) from January 2007 to May 2012. Data were compared to the results provided by the Registry of the Spanish Group on Neuroendocrine Tumors (RGETNE).
RESULTS: The study cohort comprised 78 patients. Gastroenteric nonfunctional tumors were the most common neoplasms. Metastases were found at diagnosis in50.6% of patients, with nodal involvement being most prevalent. Tumors located in the rectum were associated to the highestrate of metastasis. Overall 2-year survival rate was 74.8% and was related to sex, Ki-67 expression, and presence of metastasis.
Copyright © 2013 SEEN. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Gastrointestinal; Neuroendocrine tumors; Pancreatic; Pancreático; Supervivencia; Survival; Tratamiento; Treatment; Tumor neuroendocrino

Mesh:

Year:  2014        PMID: 24560439     DOI: 10.1016/j.endonu.2013.12.001

Source DB:  PubMed          Journal:  Endocrinol Nutr        ISSN: 1575-0922


  1 in total

1.  Clinicopathological Features and Prognostic Factors of Colorectal Neuroendocrine Neoplasms.

Authors:  Mengjie Jiang; Yinuo Tan; Xiaofen Li; Jianfei Fu; Hanguang Hu; Xianyun Ye; Ying Cao; Jinghong Xu; Ying Yuan
Journal:  Gastroenterol Res Pract       Date:  2017-01-17       Impact factor: 2.260

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.